DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
ParaNano Wound Care (PWC) solves a global problem in treatment of infection in chronic wounds: detection, notification, and early intervention. Infection in chronic wounds...
Unity Stoakes is the Co-Founder of the Startup Health organization now in its 10th year. The group centralizes their focus on 12 "Moonshots" which...
In this episode, Ryan Khanna, MD, MBA co-hosts a discussion with Robert Eastlack who runs a premier surgical spine practice in San Diego, CA...
